Drug Index

Voretigene Neparvovec

Mechanism :

Voretigene neparvovec-rzyl is an adeno-associated virus vector-based gene therapy that delivers a normal copy of the gene encoding human retinal pigment epithelial 65 kDa protein (RPE65) to retinal cells thus augmenting reduced or absent levels of biologically active RPE65. The RPE65 gene mutations lead to reduced or absent levels of RPE65 isomerohydrolase activity, blocking the visual cycle and ultimately impairing vision.

Indication :

  • Treatment of confirmed biallelic RPE65 mutation-associated retinal dystrophy.

Contraindications :

There are no contraindications listed.

Dosing :

>1 year: Subretinal: 1.5 x 1011 vector genomes in a total volume of 0.3 mL injected into each eye on separate days 6 days apart.

Adverse Effect :

Conjunctival hyperemia, cataract (including progression), increased intraocular pressure, retinal pigment epithelium tear, corneal thinning, eye disease (macular hole), retinal deposits, eye irritation, eye pain, maculopathy, ophthalmic inflammation, endophthalmitis.

Interaction :

There are no known significant interactions.

Hepatic Dose :

No dose adjustment recommended.
02/21/2024 21:51:29 Voretigene Neparvovec
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0